Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients.
Atherosclerotic calcification and osteoporosis often coexist in patients, yielding formation of bone mineral in vascular walls and its simultaneous loss from bone. To assess the potential role of lipoproteins in both processes, we examined the effects of minimally oxidized low-density lipoprotein (MM-LDL) and several other lipid oxidation products on calcifying vascular cells (CVCs) and bone-derived preosteoblasts MC3T3-E1. In CVCs, MM-LDL but not native LDL inhibited proliferation, caused a dose-dependent increase in alkaline phosphatase activity, which is a marker of osteoblastic differentiation, and induced the formation of extensive areas of calcification. Similar to MM-LDL, oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (ox-PAPC) and the isoprostane 8-iso prostaglandin E2 but not PAPC or isoprostane 8-iso prostaglandin F2 alpha induced alkaline phosphatase activity and differentiation of CVCs. In contrast, MM-LDL and the above oxidized lipids inhibited differentiation of the MC3T3-E1 bone cells, as evidenced by their stimulatory effect on proliferation and their inhibitory effect on the induction of alkaline phosphatase and calcium uptake. These results suggest that specific oxidized lipids may be the common factors underlying the pathogenesis of both atherosclerotic calcification and osteoporosis.
Parhami
F
F
Department of Medicine, University of California, Los Angeles School of Medicine, USA. fparhami@medicine.medsch.ucla.edu
Morrow
A D
AD
Balucan
J
J
Leitinger
N
N
Watson
A D
AD
Tintut
Y
Y
Berliner
J A
JA
Demer
L L
LL
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001011:Aorta; D002114:Calcinosis / Q000378:metabolism*; D002118:Calcium / Q000378:metabolism; D002417:Cattle; D002454:Cell Differentiation / Q000187:drug effects*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D015232:Dinoprostone / Q000031:analogs & derivatives* / Q000494:pharmacology; D028421:Isoprostanes; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D010006:Osteoblasts / Q000166:cytology* / Q000378:metabolism; D010024:Osteoporosis / Q000378:metabolism*; D010084:Oxidation-Reduction
D028421:Isoprostanes; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D004247:DNA; D000469:Alkaline Phosphatase; D015232:Dinoprostone; D002118:Calcium; C011987:8-isoprostaglandin E2